234 11 Small Functional Peptides and Their Application in Superfunctionalizing Proteins
91 Fayolle, C. et al. (1999) Therapy of murine tumors with recombinant Bordetella
pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J. Immunol.,
162 (7), 4157–4162.
92 Fayolle, C. et al. (1996) In vivo induction of CTL responses by recombinant
adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes.
J. Immunol., 156 (12), 4697–4706.
93 Saron, M.F. et al. (1997) Anti‐viral protection conferred by recombinant
adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell
epitope from lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. U.S.A.,
94 (7), 3314–3319.
94 Bckstrom, M. et al. (1995) Characterization of an internal permissive site in the
cholera toxin B‐subunit and insertion of epitopes from human
immunodeficiency virus‐1, hepatitis B virus and enterotoxigenic Escherichia
coli. Gene, 165 (2), 163–171.
95 Schodel, F. et al. (1996) Hybrid hepatitis B virus core antigen as a vaccine carrier
moiety: I. presentation of foreign epitopes. J. Biotechnol., 44 (1–3), 91–96.
96 Schodel, F. et al. (1996) Hybrid hepatitis B virus core antigen as a vaccine
carrier moiety. II. Expression in avirulent Salmonella spp. for mucosal
immunization. Adv. Exp. Med. Biol., 397 , 15–21.
97 Worgall, S. et al. (2005) Protection against P. aeruginosa with an adenovirus
vector containing an OprF epitope in the capsid. J. Clin. Invest., 115 (5),
1281–1289.
98 Krause, A. et al. (2006) Epitopes expressed in different adenovirus capsid
proteins induce different levels of epitope‐specific immunity. J. Virol., 80 (11),
5523–5530.
99 McConnell, M.J., Danthinne, X., and Imperiale, M.J. (2006) Characterization of a
permissive epitope insertion site in adenovirus hexon. J. Virol., 80 (11), 5361–5370.
100 Schodel, F. et al. (1992) The position of heterologous epitopes inserted in
hepatitis B virus core particles determines their immunogenicity. J. Virol., 66
(1), 106–114.
101 Matsubara, T. (2012) Potential of peptides as inhibitors and mimotopes:
selection of carbohydrate‐mimetic peptides from phage display libraries.
J. Nucleic Acids, 2012 , 740982.
102 Slovin, S.F., Keding, S.J., and Ragupathi, G. (2005) Carbohydrate vaccines as
immunotherapy for cancer. Immunol. Cell Biol., 83 (4), 418–428.
103 Boltje, T.J., Buskas, T., and Boons, G.J. (2009) Opportunities and challenges in
synthetic oligosaccharide and glycoconjugate research. Nat. Chem., 1 (8),
611–622.
104 Vlieghe, P. et al. (2010) Synthetic therapeutic peptides: science and market.
Drug Discovery Today, 15 (1–2), 40–56.
105 Scott, J.K. et al. (1992) A family of concanavalin A‐binding peptides
from a hexapeptide epitope library. Proc. Natl. Acad. Sci. U.S.A., 89 (12),
5398–5402.
106 Hancock, R.E.W. and Lehrer, R. (1998) Cationic peptides: a new source of
antibiotics. Trends Biotechnol., 16 (2), 82–88.
107 Brogden, K.A. (2005) Antimicrobial peptides: pore formers or metabolic
inhibitors in bacteria? Nat. Rev. Microbiol., 3 (3), 238–250.